论文部分内容阅读
目的:探讨归脾汤联合西药化疗用于晚期胃癌的疗效。方法:将我院晚期胃癌患者纳入研究,病理类型为低分化、中分化腺癌、高分化腺癌、印戒细胞癌、管状腺癌、粘液细胞癌。分为:研究组(治疗方案为归脾汤联合西药化疗)和对照组(治疗方案为西药化疗)。对比:(1)两组化疗2周期后治疗疗效;(2)两组毒副反应;(3)两组1年生存率。结果:(1)两组化疗2周期后缓解率分别为56%、41%,比较有差异(P<0.05);(2)研究组和对照组毒副反应结果比较无差异(P>0.05);(3)研究组和对照组1年生存率分别为38%、22%,比较有差异(P<0.05)。结论:归脾汤联合西药化疗用于晚期胃癌疗效肯定,能够延长患者生存期。
Objective: To explore Guipi Decoction combined with western medicine for the treatment of advanced gastric cancer. Methods: The patients with advanced gastric cancer in our hospital were included in the study. The pathological types were poorly differentiated, moderately differentiated adenocarcinoma, well-differentiated adenocarcinoma, signet-ring cell carcinoma, tubular adenocarcinoma and mucinous cell carcinoma. Divided into: the study group (treatment program for the spleen soup combined with western medicine chemotherapy) and the control group (treatment program for western medicine chemotherapy). Contrast: (1) two cycles of chemotherapy after treatment efficacy; (2) two groups of side effects; (3) two-year survival rate. Results: (1) The remission rates after two cycles of chemotherapy were 56% and 41%, respectively (P <0.05). (2) There was no significant difference in toxic and side effects between the two groups (P> 0.05) ; (3) The 1-year survival rates of study group and control group were 38% and 22%, respectively (P <0.05). Conclusion: Guipi Decoction combined with Western medicine for the treatment of advanced gastric cancer is positive, can prolong the survival of patients.